{
  "docId": "019de073-b41a-7298-b152-a88168c594ee",
  "docSlug": "fcd1785019fd61535487d85f646654d9",
  "documentTitle": "Enochian Biosciences | Investor Presentation Deck | 39 slides",
  "authorId": "enochian-biosciences",
  "authorName": "Enochian BioSciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7744917,
  "pageNumber": 18,
  "pageCount": 39,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide uses a ribbon-style process diagram to show progression from proof-of-concept to clinical trials.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-b41a-7298-b152-a88168c594ee/18",
  "deckHref": "/decks/019de073-b41a-7298-b152-a88168c594ee",
  "deckJsonHref": "/decks/019de073-b41a-7298-b152-a88168c594ee.json",
  "deckAnchorHref": "/decks/019de073-b41a-7298-b152-a88168c594ee#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.408,
        "w": 0.728,
        "x": 0.136,
        "y": 0.263
      },
      "kind": "diagram",
      "text": "Humanized mouse model of human pancreatic cancer Proof-of-Concept: Substantial tumor size reduction and impressive immune responses. Process & Analytical Development ongoing. Potential Pre-IND – Q1/2 2023, Potential IND Filing – Q4 2023/Q1 2024, Potential Phase I Trial – Late 2023/early 2024",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91185c73-9ba5-4de7-b37a-479029b8277a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.09
      },
      "kind": "title",
      "text": "ENOB-DC-11: CURRENT STATUS & POTENTIAL NEAR-TERM MILESTONES",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3aafe86-3a33-41cc-9c41-b44c5d17ddeb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "a8c03c38-8e5d-4e36-9442-d0cf55b17e73",
      "evidence": "The slide presents a sequence of events and milestones over time.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 18,
      "from": 13,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "00658899-9c16-4305-bf3f-2ac495041c6d",
      "evidence": "The loop opens with the problem statement (slide 13) and closes with the potential of ENOB-DC-11 (slide 18)",
      "position": 0,
      "objective": "Highlight the need for improved therapies for cancer and infectious diseases",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}